US FDA proposes excluding weight-loss drugs from compounding list
US FDA proposes excluding weight-loss drugs from compounding list
April 30 (Reuters) – The U.S. Food and Drug Administration on Thursday proposed excluding active ingredients for Novo Nordisk and Eli Lilly’s weight-loss drugs on the list of drugs outsourcing facilities can use for compounding.
If finalized, the exclusion would limit compounding of these medicines unless they appear on the agency’s drug shortage list.
The FDA said it did not identify a clinical need for outsourcing facilities to compound semaglutide, the active ingredient of Novo’s Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, from bulk drug substances. The proposal also includes Novo’s older molecule liraglutide.
“When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need,” FDA Commissioner Marty Makary said.
(Reporting by Mrinalika Roy and Mariam Sunny in Bengaluru; Editing by Leroy Leo)
Eli Lilly shares soars as sales for its GLP-1 drugs outperform.
Follow David Benavidez vs. Gilberto “Zurdo” Ramirez live results and round-by-round updates for the Cinco de Mayo fight card on Saturday in Las Vegas.
Need extra hints for today’s Strands puzzle? Here are clues and spoilers for puzzle #790.
Follow Naoya Inoue vs. Junto Nakatani live results and round-by-round updates for the historic Inoue vs. Nakatani fight card on Saturday in Tokyo, Japan.
This has somehow happened twice for the Raptors.
Orlando missed 23 consecutive 2nd-half shots and went 1-of-20 in the 4th quarter as Cade Cunningham got going to send the series back to Detroit
Toronto hasn’t seen a fortunate bounce like that since Kawhi Leonard’s game-winner in 2019.
The Magic missed 23 straight shots. Twenty-three.
College sports have never been more defined by money than they are right now. We know who’s in the lead there.
The injury bug has bitten Baltimore badly so far this year.
Powered by WPeMatico




















